ClinicalTrials.gg
Active, not recruitingNCT06386003Updated Oct 6, 2026

Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD

A Phase 2 interventional study of Psilocybin in Post Traumatic Stress Disorder, PTSD and Chronic PTSD, sponsored by Unity Health Toronto. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Unity Health Toronto · Phase 2, Interventional, and Treatment

How we know

Updated Oct 6, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
15th of 20
15 · median 33
Started
2026
with 6 others
Phase 2
10 of 20
5 open now
Primary completion
2028-01
later than 11 of 15 live
Registered
9th of 20
by date

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 15th largest by planned enrollment, is one of 7 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 11 of the 15 other live ones, and was the 9th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).

Read the detailed description

Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.

Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.

03

Conditions studied

  • Post Traumatic Stress Disorder
  • PTSD
  • Chronic PTSD

Keywords

  • Post Traumatic Stress Disorder
  • Psilocybin
  • Cognitive Processing Therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet Diagnostic and Statistical Manual-5th edition () criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
  2. Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
  3. Are willing to refrain from taking any psychiatric medications during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of ;
  2. Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
  3. Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
  4. Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
  5. History of seizure disorder;
  6. Uncontrolled insulin-dependent diabetes;
  7. Recent stroke, intracranial or subarachnoid hemorrhage (\< 1 year from signing of form [ICF]), recent myocardial infarction (\< 1 year from signing of ICF), arrhythmia (\< 1 year from signing of ICF);
  8. Have liver disease with the exception of asymptomatic subjects with who have previously undergone evaluation and successful treatment;
  9. Lifetime history of substance-induced psychosis;
  10. Lifetime history of substance use disorder with a hallucinogen;
  11. History of alcohol use disorder in the past 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Experimental

    Single dose of psilocybin 25mg + Massed cognitive processing therapy

    Drug: Psilocybin

Interventions

  • Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days.

06

What researchers measure

Primary outcomes

  1. Feasibility and tolerability

    Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events.

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score

    The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms.

    Time frame: Up to 16 weeks

  2. Posttraumatic stress disorder Checklist-5 (PCL-5)

    The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD.

    Time frame: Up to 16 weeks

  3. Patient Health Questionnaire-9 (PHQ-9)

    The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).

    Time frame: Up to 16 weeks

  4. Generalized Anxiety Disorder Scale, 7-item (GAD-7)

    Total score ranges from 0 to 21; a higher score denotes greater symptom severity.

    Time frame: Up to 16 weeks

  5. Dissociative Experiences Scale II (DES-II)

    The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences.

    Time frame: Up to 13 weeks

  6. Pittsburgh Sleep Quality Index (PSQI)

    The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval.

    Time frame: Up to 13 weeks

  7. World Health Organization Well-Being Index, 5-item (WHO-5)

    The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life.

    Time frame: Up to 16 weeks

  8. Quality of relationships inventory (QRI)

    The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true.

    Time frame: Up to 13 weeks

  9. Inventory of psychosocial functioning (IPF)

    The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days.

    Time frame: Up to 13 weeks

  10. Posttraumatic Maladaptive Beliefs Scale (PMBS)

    The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure.

    Time frame: Up to 13 weeks

  11. Brief Experiential Avoidance Questionnaire (BEAQ)

    The BEAQ is a 15-item self-report measure of experiential avoidance.

    Time frame: Up to 13 weeks

  12. 24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)

    The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility.

    Time frame: Up to 13 weeks

  13. Working Alliance Inventory- Short Form (WAI-SF)

    The WAI-SF is a patient-rated measure of the alliance between a therapist and client.

    Time frame: Up to Day 7

  14. Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)

    The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults.

    Time frame: Up to 13 weeks

  15. Self-Compassion Scale-Short Form (SCS-SF)

    The SCS-SF is a 12-item self-report measure of self-compassion.

    Time frame: Up to 13 weeks

  16. Psychological Insight Questionnaire (PIQ)

    The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic.

    Time frame: Up to Day 3

  17. Emotional Breakthrough Inventory (EBI)

    The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state.

    Time frame: Up to Day 3

  18. Altered States of Consciousness Rating Scale (ASC)

    The ASC measures altered states of consciousness.

    Time frame: Up to Day 3

  19. Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)

    The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility.

    Time frame: Up to Day 3

  20. Childhood Trauma Questionnaire-short form (CTQ-SF)

    Time frame: Screening

Other outcomes

  1. Effect on digital physiological passive data collected through the use of a wearable device

    Example: sleep, activity

    Time frame: Up to 16 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Meshkat S, J Zeifman R, Stewart K, Janssen-Aguilar R, Lou W, Jetly R, Monson CM, Bhat V. Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial. PLoS One. 2025 Jan 17;20(1):e0313741. doi: 10.1371/journal.pone.0313741. eCollection 2025. PubMed 39823496 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 19 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Jan 2027 → Jan 2028 and completion Jan 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2024
First posted
Apr 26, 2024
StartActual
Jun 1, 2026
Primary completionEst.
Jan 2028was Jan 2027
CompletionEst.
Jun 2028was Jan 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 6, 2026
Primary completion
Jan 2027→Jan 2028
Oct 6, 2026
Study completion
Jan 2027→Jun 2028
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Active, not recruiting
    Primary completion Jan 2027→Jan 2028
    Study completion Jan 2027→Jun 2028
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06386003
Collaborators
Toronto Metropolitan University, University of Ottawa
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Jun 1, 2026
Primary completion
Jan 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion